79 results
8-K
EX-10.4
NKGN
NKGen Biotech Inc
10 May 24
Entry into a Material Definitive Agreement
4:01pm
of internal accounting controls sufficient, in the judgment of the Company’s board of directors, to provide reasonable assurance that (i
8-K
EX-10.6
NKGN
NKGen Biotech Inc
10 May 24
Entry into a Material Definitive Agreement
4:01pm
of directors, to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii
8-K
EX-10.2
e8wdt0 vygkemqce9di9
10 May 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.3
any6l8g3u8 p2do
11 Apr 24
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
8:05am
8-K
EX-10.1
cud4gyikp 34ff51t
11 Apr 24
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
8:05am
8-K
EX-10.2
9kjaq2zmhq3evx9rr8
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.4
zqhzir5kdu7e2
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.2
swo1cbpt01pn
27 Mar 24
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.4
pu377owkk1lslxi7ohrn
27 Mar 24
Entry into a Material Definitive Agreement
4:55pm
8-K
7z5lj90ia 8qzlt
15 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:02pm
8-K
EX-99.1
i7bnxaijobhymuki7yo
14 Nov 23
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
4:36pm